| Literature DB >> 34001295 |
Claire L Niedzwiedz1, Michaela Benzeval2, Kirsten Hainey3, Alastair H Leyland3, Srinivasa Vittal Katikireddi3.
Abstract
Studies exploring the longer-term effects of experiencing coronavirus disease-2019 (COVID-19) on mental health are lacking. We explored the relationship between reporting probable COVID-19 symptoms in April 2020 and psychological distress (measured using the General Health Questionnaire) 1, 2, 3, 5 and 7 months later. Data were taken from the UK Household Longitudinal Study, a nationally representative household panel survey of UK adults. Elevated levels of psychological distress were found up to 7 months after probable COVID-19, compared with participants with no likely infection. Associations were stronger among younger age groups and men. Further research into the psychological sequalae of COVID-19 is urgently needed.Entities:
Keywords: COVID-19; Epidemiology; depressive disorders; infectious disease; mental health
Year: 2021 PMID: 34001295 PMCID: PMC8134894 DOI: 10.1192/bjo.2021.63
Source DB: PubMed Journal: BJPsych Open ISSN: 2056-4724
Associations between probable coronavirus disease-2019 (COVID-19) in April 2020 and psychological distress (General Health Questionnaire (GHQ-12) ‘case’) up to 7 months later stratified by age group and gender
| 1 month later | 2 months later | 3 months later | 5 months later | 7 months later | |
|---|---|---|---|---|---|
| Overall | |||||
| No likely infection (reference) | 1 | 1 | 1 | 1 | 1 |
| Probable infection, | 1.39** (1.10–1.76) | 1.38* (1.05–1.81) | 1.31 (0.99–1.72) | 1.42* (1.05–1.92) | 1.47* (1.04–2.07) |
| 12 492 | 11 949 | 11 563 | 11 009 | 10 379 | |
| By gender | |||||
| Men, OR (95% CI) | 1.52* (1.05–2.20) | 1.57* (1.04–2.37) | 1.43 (0.91–2.24) | 1.36 (0.88–2.12) | 1.77** (1.20–2.61) |
| 5138 | 4908 | 4759 | 4556 | 4283 | |
| Women, OR (95% CI) | 1.30 (0.98–1.75) | 1.31 (0.94–1.81) | 1.25 (0.86–1.82) | 1.46 (0.98–2.19) | 1.30 (0.82–2.07) |
| 7279 | 6969 | 6730 | 6379 | 6022 | |
| By age group | |||||
| Under 45 years, OR (95% CI) | 1.51* (1.07–2.13) | 1.43 (0.91–2.26) | 1.20 (0.80–1.78) | 1.39 (0.89–2.18) | 1.74* (1.02–2.95) |
| 3426 | 3169 | 2996 | 2735 | 2481 | |
| 45–64 years, OR (95% CI) | 1.24 (0.81–1.90) | 1.39 (0.87–2.22) | 1.38 (0.85–2.25) | 1.53 (0.94–2.49) | 1.27 (0.67–2.38) |
| 5279 | 5045 | 4924 | 4724 | 4485 | |
| ≥65 years, OR (95% CI) | 1.16 (0.52–2.58) | 1.14 (0.63–2.04) | 1.33 (0.68–2.60) | 1.23 (0.52–2.92) | 1.14 (0.59–2.20) |
| 3547 | 3511 | 3432 | 3329 | 3203 | |
Results for each time point include people who participated in wave 9, April 2020 and the respective follow-up wave from May to November 2020.
Adjusted for age, gender, ethnicity, limiting long-standing illness, GHQ-12 at wave 9 (2017–19).
*P < 0.05, **P < 0.01, ***P < 0.001.